Phase 1/2 Clinical Study of Lutetium Lu 177 JH020002 Injection in Patients With Advanced Prostate Cancer

This Phase 1/2 study tests a new targeted radiation therapy drug called Lutetium Lu 177 JH020002 in men with advanced prostate cancer. The drug delivers radiation directly to prostate cancer cells throughout the body, potentially treating cancer that has spread. **You may be eligible if...** - You are male and 18 or older - You have a confirmed diagnosis of prostate adenocarcinoma - Your testosterone is at castrate levels (less than 50 ng/dL) — meaning you are on hormone therapy or surgically castrated - Your overall health is good (ECOG 0–2) - Your life expectancy is more than 6 months - You meet blood count and organ function requirements **You may NOT be eligible if...** - You have neuroendocrine or small cell prostate cancer features - You have had another cancer (with some exceptions for treated skin cancers) - You do not meet the performance status or organ function requirements - Your testosterone is not at castrate levels Talk to your doctor to see if this trial is right for you.